Jo J et al., 2023-03-20: In TRAMP transgenic mice, systemically administered methylene blue polyacrylamide nanoparticles labelled proliferating prostate cancer cells and let photoacoustic spectral analysis distinguish normal from cancerous prostate and low- from high-grade cancer (18 mice). An imaging study, not a treatment study.
In this study, in a transgenic mouse (TRAMP) model of PCa, we utilized methylene blue polyacrylamide nanoparticles (MB PAA NPs) to label the cancer cells in prostate in vivo.
Jo J et al., 2023-03-20: In TRAMP transgenic mice, systemically administered methylene blue polyacrylamide nanoparticles labelled proliferating prostate cancer cells and let photoacoustic spectral analysis distinguish normal from cancerous prostate and low- from high-grade cancer (18 mice). An imaging study, not a treatment study. C2 (also C4). Study type: animal (transgenic TRAMP mouse model of prostate cancer), imaging. N: 18 mice. Country: USA (University of Michigan, Ann Arbor). Dose: not stated in the abstract; MB delivered as polyacrylamide nanoparticles, systemic administration. Route: systemic; schedule not stated. Light: photoacoustic excitation, wavelength not stated in the abstract. Funder: NIH R01 CA250499, R01 DK125687, R37 CA222829, P01 CA093900 and a Prostate Cancer Foundation award (19YOUN12). Conflicts: 'The authors declare no conflict of interest.' Maker: laboratory-made MB polyacrylamide nanoparticles. Comparator: histopathology grading; normal vs cancer tissue. No survival or tumour-growth endpoint. Study type: animal.
